Unlock stock picks and a broker-level newsfeed that powers Wall Street.

NSE - Delayed Quote INR

ZIM Laboratories Limited (ZIMLAB.NS)

88.07
-3.00
(-3.29%)
At close: April 25 at 3:29:47 PM GMT+5:30
Loading Chart for ZIMLAB.NS
  • Previous Close 91.07
  • Open 92.49
  • Bid --
  • Ask --
  • Day's Range 87.86 - 92.49
  • 52 Week Range 79.49 - 128.90
  • Volume 44,113
  • Avg. Volume 134,495
  • Market Cap (intraday) 4.444B
  • Beta (5Y Monthly) 0.55
  • PE Ratio (TTM) 27.96
  • EPS (TTM) 3.15
  • Earnings Date May 12, 2025 - May 16, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

ZIM Laboratories Limited engages in the development, manufacture, and supply of generic pharmaceutical and nutraceutical products in India and internationally. The company provides its products in pre- formulation intermediates and finished formulations in the oral solid dosage forms, such as pellets, taste-masked powders, granules, tablets, capsules, dry syrup, and oral thin films. It offers therapeutics in the areas of urology, gastroenterology, antibiotics, anti-infectives, cardiovascular, central nervous system, NSAIDs/pain analgesics, and vitamins and supplements. The company was incorporated in 1984 and is based in Nagpur, India.

www.zimlab.in

556

Full Time Employees

March 31

Fiscal Year Ends

Recent News: ZIMLAB.NS

View More

Performance Overview: ZIMLAB.NS

Trailing total returns as of 4/25/2025, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .

YTD Return

ZIMLAB.NS
18.09%
S&P BSE SENSEX (^BSESN)
1.37%

1-Year Return

ZIMLAB.NS
29.20%
S&P BSE SENSEX (^BSESN)
6.56%

3-Year Return

ZIMLAB.NS
21.37%
S&P BSE SENSEX (^BSESN)
40.00%

5-Year Return

ZIMLAB.NS
21.37%
S&P BSE SENSEX (^BSESN)
152.86%

Compare To: ZIMLAB.NS

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: ZIMLAB.NS

View More

Valuation Measures

Annual
As of 4/25/2025
  • Market Cap

    4.28B

  • Enterprise Value

    5.23B

  • Trailing P/E

    27.96

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.14

  • Price/Book (mrq)

    1.77

  • Enterprise Value/Revenue

    1.39

  • Enterprise Value/EBITDA

    10.59

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    3.96%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    3.88B

  • Net Income Avi to Common (ttm)

    153.66M

  • Diluted EPS (ttm)

    3.15

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    58.15M

  • Total Debt/Equity (mrq)

    41.48%

  • Levered Free Cash Flow (ttm)

    --

Research Analysis: ZIMLAB.NS

View More

Company Insights: ZIMLAB.NS

Research Reports: ZIMLAB.NS

View More

People Also Watch